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Abstract
Background
Current treatment options for chronic pain and depression are largely medication-based,
which may cause adverse side effects. Integrative Medical Group Visits (IMGV) combines
mindfulness techniques, evidence based integrative medicine, and medical group visits,
and is a promising adjunct to medications, especially for diverse underserved patients who
have limited access to non-pharmacological therapies.
Objective
Determine the effectiveness of IMGV compared to a Primary Care Provider (PCP) visit in
patients with chronic pain and depression.
Design
9-week single-blind randomized control trial with a 12-week maintenance phase (interven-
tion—medical groups; control—primary care provider visit)
Setting
Academic tertiary safety-net hospital and 2 affiliated federally-qualified community health
centers.
Participants
159 predominantly low income racially diverse adults with nonspecific chronic pain and
depressive symptoms.
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Interventions
IMGV intervention– 9 weekly 2.5 hour in person IMGV sessions, 12 weeks on-line platform
access followed by a final IMGV at 21 weeks.
Measurements
Data collected at baseline, 9, and 21 weeks included primary outcomes depressive symp-
toms (Patient Health Questionnaire 9), pain (Brief Pain Inventory). Secondary outcomes
included pain medication use and utilization.
Results
There were no differences in pain or depression at any time point. At 9 weeks, the IMGV
group had fewer emergency department visits (RR 0.32, 95% CI: 0.12, 0.83) compared to
controls. At 21 weeks, the IMGV group reported reduction in pain medication use (Odds
Ratio: 0.42, CI: 0.18–0.98) compared to controls.
Limitations
Absence of treatment assignment concealment for patients and disproportionate group
attendance in IMGV.
Conclusion
Results demonstrate that low-income racially diverse patients will attend medical group vis-
its that focus on non-pharmacological techniques, however, in the attention to treat analysis
there was no difference in average pain levels between the intervention and the control
group.
Trial registration
clinicaltrials.gov NCT02262377.
Introduction
Chronic pain annually affects 25 million adults in the United States and is linked to significant
disability and high medical utilization [1–3]. Treatment of chronic pain is complex due to
safety concerns of prescription pain medications (e.g. opioids) and comorbid conditions such
as depression and substance use [4,5]. Depression often complicates the treatment of chronic
pain [6,7]. Even when pain medications are effective in reducing pain; they may not improve
mental and functional status and may actually increase depression [8,9]. Furthermore, patients
with chronic pain and depressive symptoms have increased use of medical care and higher risk
of medical utilization [10–12].
Due to socioeconomic factors, treating chronic pain and depressive symptoms may be chal-
lenging in a low income, racially and ethnically diverse patients [13,14]. Disparities in access to
prescription and non-prescription treatment for chronic pain and associated conditions may
contribute to negative impact on economic (ability to work), emotional (social isolation), and
daily functioning [15–17]. For example, minority patients with chronic pain receive less
patient education, medications, surgery, and specialty referrals [14]. Access to non-pharmaco-
logical therapies is challenging as these therapies are often located far from low income
IMGV and its effectiveness on chronic pain and depression
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neighborhoods, require an out of pocket payment, may not be covered by health insurance,
and are less likely to be offered as a treatment to low-income or under-represented minority
patients [18–23].
One such non-pharmacological treatment is Evidence Based Integrative Medicine (EBIM)
which combines “mainstream medical therapies and complementary therapies for which there
is high-quality scientific evidence of safety and effectiveness” [24,25]. EBIM addresses factors
such as activity, social connection, nutrition, lifestyle modification, and stress, all of which play
significant roles in chronic conditions [26]. Clinical studies on EBIM demonstrate health
improvements in patients’ chronic pain and/or depressive symptoms [27]. For example, mind
body techniques, such as Mindfulness Based Stress Reduction (MBSR), demonstrate benefits
for individuals with chronic pain [8,9,28]. Several systematic reviews on mindfulness clinical
trials for patients with chronic pain show improvement in pain scores and mental health status
[5, 29–32].
In 2012, at Boston Medical Center, an urban safety-net hospital, the Integrative Medical
Group Visit (IMGV) was developed to increase access to EBIM for patients in the outpatient
setting. IMGV combines a medical group visit (MGV), principles of mindfulness, and EBIM
[33,34]. We chose to use the medical group visit as the means to deliver EBIM for the following
reasons: clinicians can bill insurance for the medical group visit, it increases access to EBIM,
patients were introduced to EBIM in a trusted environment, and the medical group visits
could be conducted in local neighborhood community health centers affiliated with BMC [35–
37]. Medical group visits (shared medical appointments) are comprised of two clinicians who
treat a group of eight to twelve patients at one time and include: individual medical attention,
patient education, self-management, self-monitoring, and social support. MGVs are used to
treat an increasing number of chronic illnesses and improve symptom management [38]. Cur-
rent literature suggests that MGVs improve health-related quality of life, patient satisfaction,
and reduce health care utilization [39,40].
In an uncontrolled study, the IMGV model demonstrated the potential for reducing pain
and depressive symptoms [40]. Additionally, it was found to increase quality of life and reduce
Emergency Department (ED) use [33]. However, it is unknown how the IMGV compares to a
Primary Care Provider (PCP) visit in socioeconomically diverse patients with chronic pain
and depressive symptoms [33,41–43]. This paper reports the main outcome findings of a single
blind randomized controlled trial comparing the effectiveness of an IMGV in reducing pain,
depressive symptoms, and pain medication use to a primary care visit. Our primary hypothesis
was a greater reduction in pain, depressive symptoms, and medication use for participants ran-
domized to IMGV compared with participants randomized to the control group. Additionally,
this analysis examines who attended the IMGV and correlates of high versus low IMGV
attendance.
Materials and methods
The study was approved by the Boston University Medical Campus Institutional Review Board
(IRB) and the community health center’s (CHC) research committees (IRB Approval Number:
H33096). We registered this randomized controlled trial (RCT) in the international trial regis-
ter [ClinicalTrials.gov: Identifier NCT02262377]. For further detail please refer to our methods
paper [34].
This RCT was conducted at an ambulatory primary care clinic at the Boston Medical Center
(BMC) and two affiliated federally qualified Community Health Centers (CHC): Codman
Square Health Center (CSHC) and DotHouse Health (DH). These practices serve low-income,
racially and ethnically diverse populations living in the Boston area. Our inclusion criteria
IMGV and its effectiveness on chronic pain and depression
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included: age 18 years or older, able to communicate in English language, score of� 5 on the
Patient Health Questionnaire-9 (PHQ-9), score of� 4 on a 0–10 scale measuring daily chronic
pain intensity for at least 12 weeks, and having a PCP located at the site where the IMGV was
being held [43–47]. The exclusion criteria included: self-reported symptoms of psychosis or
mania, active substance abuse (alcohol, cocaine or heroin use in the last 3 months), previous
participation in an IMGV, a new pain treatment in the past month or plans to begin any new
pain treatments in the next three months, active suicidality, any other severe disabling chronic
medical or psychiatric co-morbidities preventing attendance to the IMGV, or no access to the
internet during the study period [34].
Participants were recruited through their clinicians’ outpatient referral, clinicians’ letter to
patients about the study, or self-referral. After being contacted by the research assistant (RA),
patients then consented to be screened. If the eligibility was verified and there was patient writ-
ten consent, the patient was next enrolled in the study.
This study is a single-blinded, two-arm randomized controlled trial. All participants
(N = 155) who were consented and completed baseline assessments were randomized (1:1) to
either intervention (IMGV) or control group. A randomization list was created using com-
puter-generated permuted blocks with a block size of 6. We used the Studytrax database sys-
tem to designate the treatment assignments. These were placed in opaque, sequentially
numbered, sealed envelopes, which were only opened by a research assistant when a new
enrolled participant received their treatment allocation. The investigators and biostatisticians
were blinded to the treatment assignment. Patients were not blinded to allocation due to the
group nature of the intervention. All patients in the control group were offered to access to the
IMGV groups after study completion.
IMGV Intervention
The IMGV intervention includes three concurrent deliveries of the same self- management
curriculum delivered with different formats–an in-person MGV, and two adjunct companion
technologies available on a computer tablet provided to the intervention participant. The first
technology was the Our Whole Lives (OWL), an e-Health toolkit platform, and the second
technology was an Embodied Conversational Agent (ECA).
A detailed description of the IMGV self management intervention has previously been
described [34]. The IMGV consists of a total of ten in-person medical group visits each lasting
2.5-hours conducted weekly from week 1 to week 9 (9 in-person sessions plus OWL/ECA).
This is followed by a 12-week maintance phase where there is access to the technology only
(OWL/ECA). A tenth and final in-person session is conducted at week 21.
At the start of the IMGV, participants measured their vital signs, moodstate, and pain levels.
They then met individually with a trained physician (a co-facilatator) for a medical assessment.
Two trained non-physician facilitators (see below) then led mindfulness practices. Patients were
instructed in the principles of mindfulness and EBIM self-management techniques (such as acu-
pressure and massage). Each week, the physician facilitated a discussion on health topics such as
stress, insomnia, depression, chronic pain cycle, activity, and healthy food choices. Finally, the
IMGV ended with a healthy meal, which mirrored the healthy nutrition topic in each session.
In addition to a physician, an experienced co-facilitator with training in mindfuness (certi-
fied MBSR instructor, yoga and meditation teacher) attended all groups. Facilitators were
mentored via direct observation of two pilot group visits, one-on-one meetings, and phone
calls by an experienced MBSR trained faculty.
To reinforce all content delivered in the in-person group, an internet-based platform called
Our Whole Lives (OWL) delivered the same in-person curriculum. OWL could be accessed
IMGV and its effectiveness on chronic pain and depression
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with a computer, smart phone, or tablet. The ECA, a female automated character, emulated
the conversational behavior of an empathic coach [48]. The ECA (Gabby) reviewed all the con-
tent discussed in the IMGV with the participants outside of the in-person group. A Dell Venue
8 Pro tablet was distributed to all intervention participants in the first session of the group.
Results of the use of technology will be published in an additional manuscript.
After the nine-week in-person group visit phase concluded, the intervention participants
entered a 12-week maintenance phase. The intervention participants retained the study tablet
and continued to have access to the ECA and the OWL website. At the end of the 21 weeks,
there was one final in-person group visit.
A trained study RA directly observed all groups and assessed the facilitator’s adherence to
the intervention components through a monitoring and evaluation checklist. These checklists
were used to assess each MGV session at all sites during the study.
Prior to the start of the study, we provided continuing medical education training in evi-
dence based chronic pain management at the study sites. We also provided access to the educa-
tional content on safe prescribing practices for chronic pain patients available on a website
(http://mytopcare.org/) through small group presentations and/or Grand Round presentations
at each study site for staff and clinical providers [49]. We did not collect data on who attended
the training.
All participants randomized to the control group were asked to visit their PCP during the
study period (baseline to 21 weeks). We verified a PCP clinical visit, via electronic medical
record (EMR) documentation. We did not collect data on the duration or content of the visit.
Outcomes
Research assistants collected outcome data at baseline, 9 weeks, and 21 weeks. Self-reported
data included: baseline demographics (age, gender, race, ethnicity, income, work status, educa-
tion) and types of pain medications used in the last seven days.
Our primary outcomes included: 1) self-reported pain measured by the Brief Pain Inven-
tory [(BPI) pain interference, pain severity, and average pain score in the last seven days]
[45,50] and 2) depression level measured by the PHQ-9, a self-reported depression scale
[49,50]. BPI pain interference, pain severity, and average pain are on a 0-10-point scale. The
higher the score, the more severe the pain. PHQ-9 is on a 0-27-point scale. The higher the
score, the more severe the depression.
Secondary outcomes included pain self-efficacy, self-reported pain medication use, health-
related quality of life, patient activation, risk of opioid misuse, and ED use [51–60]. Pain self-
efficacy was measured with the Pain Self-Efficacy Scale (PSEQ) and ranged from 0–60 points.
High PSEQ scores are associated with higher confidence to function with pain [61]. For self-
reported pain medication use, we used the Timeline Follow Back method to determine patient
reported use of pain medications in the prior seven days [51, 62]. We categorized pain medica-
tions by opioids (MS Contin, Vicodin, Oxycodone, OxyContin, Tramadol, Tylenol with
Codeine #3), Nonsteroidal Anti-inflammatory Drugs (NSAIDS: Ibuprofen, Naproxen, Aspi-
rin), and other pain medication (Acetaminophen, Cyclobenzaprine, Gabapentin).
Health-related quality of life was measured using the Short form 12 Health Survey version 2
(SF-12). The SF-12 is composed of two component scores: Mental Component Summary
(MCS) and Physical Component Summary (PCS) [63]. SF-12 scores ranged from 0–100
points, where a zero score indicates the lowest level of health and 100 indicates the highest
level of health. Activation in patients was measured using Patient Activation Measure (PAM)
[52,55]. PAM scores are transformed to a scale of 0–100 points. The risk of opioid misuse was
measured using the Common Opioid Misuse Measure (COMM) [58, 64]. COMM is a 17-item
IMGV and its effectiveness on chronic pain and depression
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assessment measure and scored based on a Likert 5-point scale from 0–4. The COMM cut-off
score of 9 or above is a positive indicator for misusing medication.
We measured ED utilization for the 12 weeks prior to the study and throughout the study
period through self-reported ED use at baseline, 9 weeks, and 21 weeks and through the EMR.
After completing the 9 and 21-week data collection, patients received a $25 gift card incentive.
We assumed a two-sided alpha error = 0.05 and estimated a 20% dropout rate from baseline
to 21-weeks. Based on previous literature, we defined a statistically significant change in effect
size to include reductions in average pain from the BPI (1.5 points) and PHQ-9 (4 points)
[65,66]. Although some debate exists on how to define a minimal clinically important change,
many pain researchers consider changes in pain of more than 1–1.5 points to be clinically
important [67]. A sample size of 62 participants per treatment group across all sites had an
80% power to detect a 1.5 difference in average pain and a sample size of 31 per treatment
group had 80% power to detect a difference of 4 points in PHQ-9 score. Additionally, we
defined a clinical meaningful result as a 1.5 reduction in average pain or 4-point reduction in
PHQ-9 score [65,66].
Data analysis
We performed descriptive data analysis for baseline demographics. Means and standard devia-
tions were calculated for continuous variables, and frequencies and percentages were calcu-
lated for categorical variables. To examine the success of randomization, we applied Pearson’s
Chi-Square Test and Fisher’s Exact Test (categorical variable), and two-sample T-Test and
Wilcoxon Rank-Sum Test (continuous variable) to compare the results between intervention
and control at baseline, with a significance level of 0.1. Variables that were significantly differ-
ent across study groups at baseline were considered confounders and were adjusted for in the
following analysis. All data were analyzed using SAS 9.3. [68].
The primary analysis was intention-to-treat analysis. The ITT analysis included all partici-
pants who were randomized in the study, regardless of adherence to attending the IMGV or
attending a PCP visit (control). To address missing data in all analyses, we used multiple impu-
tation approach with 20 imputed data sets.
We performed the ITT analyses for the primary (pain and depressive symptoms) and sec-
ondary outcome variables. Descriptive statistics were calculated for all the outcome variables
(Mean, SD, or N, %). Histograms were created to assess if the variables were normally distrib-
uted. Sensitivity analysis was performed on all multivariable regressions and logistic
regressions.
For primary and secondary outcomes, we used multivariable regression models fit with
generalized estimating equations (GEEs) to account for serially collected data, with an indica-
tor for treatment assignment as the predictor of interest. We adjusted our models for potential
confounders and assessed effect modification. For continuous and count variables we consid-
ered different regression models (Poisson, Negative Binomial, and Log Normal Model, as
appropriate) to obtain the best fit for our outcomes. The models with lowest Akaike Informa-
tion Criteria (AIC) were selected. Dichotomous outcomes (any pain medication use, opioid
use, NSAIDS use, and other medication use) were fit with logistic regression. An interaction
term of time and treatment was included in our models to assess for changes in the treatment
over time.
On the advice of our patient advisory group and scientific advisory group, we conducted an
exploratory per-protocol attendance analysis to understand how the “exposure to amount of
health care”affected outcomes in those participants with no PCP visits during the study, low
attendance to IMGV (1–4 sessions), medium attendance (5–6 sessions), and high attendance
IMGV and its effectiveness on chronic pain and depression
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(7–10 sessions). We examined the baseline characteristics as well as longitudinal multivariable
regressions, comparing intervention participants who attended different numbers of sessions
to the control participants who did and did not attend PCP visits. The predictor of interest was
treatment assignment, which indicated either the number of IMGV sessions attended (1–4 ses-
sions, 5–6 sessions, and 7–10 sessions), or the control PCP visits (� 1 PCP visit, and no PCP
visit). Poisson and negative binomial models were selected where AIC was minimized. Poten-
tial confounders were adjusted for in all models. A significance level of 0.05 was used, except
where otherwise noted [68]. As we are performing multiple analyses, it is possible that we will
see p-values that are below 0.05 by chance alone. Therefore, we do not strictly interpret statisti-
cal significance at the 0.05 level for analyses beyond the primary aims of the study and view
these results as suggestive of areas that might merit further study.
Data on adverse events were reviewed and monitored on a quarterly basis by the PI. A Data
Safety Monitoring Board (DSMB) reviewed all adverse events, data collection, and adherence
to research protocol independently of study staff. All participants were included in the safety
analyses using descriptive statistics.
Results
Screening, eligibility, randomization, and reasons of participants’ ineligibility after enrollment
or withdrawal are given in Fig 1.
The recruitment began in November 2014 and finished in October 2016. Three hundred
forty-three patients were assessed for eligibility, 209 patients were eligible, and 159 were
enrolled and randomized to intervention (80) or control (79).
Four participants in intervention group were excluded from the analysis because they with-
drew their consent after being enrolled. A total of 155 participants were included in the ITT
analysis and baseline tables. After being enrolled in the study, three participants in the inter-
vention were found to meet an exclusion criterion and were discontinued. These participants
were included in the demographic descriptive analysis (Table 1), but not for 9- and 21-week
ITT analysis.
Baseline characteristics
Baseline demographic characteristics are listed in Table 1. Of the 155 participants, the average
age was 51 years old, 86% identified as female, 56% identified as black, 36% identified as
“other” race, and 19% identified as white. There were no significant differences for baseline
characteristics.
Common co-morbidities in the participants were hypertension (41%), obesity (37%), diabe-
tes (23%), insomnia (26%), anxiety (28%), Post-Traumatic Stress Disorder (PTSD) (16%), and
any substance use disorder (25%).
The baseline, 9 week, and 21 week measurements of the primary and secondary outcomes
are listed in Tables 2–4. At baseline, the average PHQ-9 score for depressive symptoms was 12,
which is characterized as moderate depression. Eighty-five percent of participants used pain
medication in the last seven days at baseline (opioids: 37%, NSAIDS 48%, other medication:
43%). The average Physical Composite Score (PCS) was 34 and the average Mental Composite
Score (MCS) was 36, compared to national average scores of 50. There were significant differ-
ences between the intervention and control group for patient activation measure (p = 0.051)
and current opioid misuse measures (COMM) (p = 0.0495) at a significant level of 0.1, so they
were adjusted for in all subsequent models.
In ITT analysis (Table 5), we found no clinically or statistically significant difference
between two groups for average pain (RR: 1.03, 95% CI: 0.92, 1.15) or PHQ-9 score (RR: 1.09,
IMGV and its effectiveness on chronic pain and depression
PLOS ONE | https://doi.org/10.1371/journal.pone.0225540 December 18, 2019 7 / 20
95% CI: 0.92, 1.28) at 9 weeks. For the primary outcomes at 21 weeks, there was no difference
of average pain (RR: 0.98, 95% CI: 0.88, 1.08) and PHQ-9 score (RR: 0.89, 95% CI: 0.75, 1.06)
for those in the intervention group compared with the control group. Participants who
attended the intervention group, there was a 4-point reduction (baseline– 13 points / 21
weeks– 9 points) in PHQ-9 compared with the control group (baseline– 11 points / 21 weeks–
10 points). This translates into a clinically meaningful difference.
For secondary outcomes, at 9 weeks there was no difference in PCS (RR: 1.01, 95% CI: 0.92,
1.12), but was lower at 21 weeks (RR = 0.86 (0.77, 0.97)). At 21 weeks, the intervention group
had higher mental quality of life compared with the control group (RR: 1.07, 95% CI: 1.01,
1.12). Although not significant at 9 weeks, at 21 weeks the intervention group had a reduction
in any pain medication use compared with the control (OR = 0.42 (0.18, 0.98)). We found that
Fig 1. Participant flow in CONSORT diagram.
https://doi.org/10.1371/journal.pone.0225540.g001
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at 9 weeks, the intervention group had fewer ED visits (RR = 0.31 (0.10, 0.89)) (baseline inter-
vention n = 15 reduced to n = 6) (baseline control n = 11 increased to n = 13) compared with
control group, but this was not maintained at 21 weeks. There was no meaningful change in
the pain severity and pain interreference between the intervention and the control group at 9
and 21 weeks.
Exploratory attendance to group visits
In terms of attendance, the minimum number of sessions attended was zero and the maximum
was ten. The average number of sessions attended was 6.1 (S.D. = 2.9) and the mode is 5.
Recorded reasons for no attendance included: lack of transportation, death of family or
Table 1. Baseline demographics for participants by group.
Variable Totals�
(N = 155)
Intervention
(N = 76)
Control
(N = 79)
P-Value
Mean (SD) Mean (SD) Mean (SD)
Age (22–84) 50.5 (12.3) 50 (12.2) 51 (12.4) 0.62
Gender N % N % N %
Female 134 86 64 84 70 89 0.42
Male 21 14 12 16 9 11
Race
White 29 19 12 16 17 21.5 0.83
Black 87 56 44 58 43 54
Multiple race 9 6 5 7 4 5
Unknown or Not Reported 30 30 15 20 16 19
Ethnicity
Hispanic 22 14 10 13 12 15 0.71
Non-Hispanic 133 86 66 87 67 85
Study Sites
BMC 68 44 33 43 35 44 0.94
DHHC 40 26 19 25 21 27
CSHC 47 30 24 32 23 29
Income
Less than $5K 20 13 9 12 11 14 0.78
$5K-$29.99K 77 50 36 47 41 52
$30K and over 13 8 6 8 7 9
Refused/DK/None 45 29 25 33 20 25
Work Status
Full/Part time 32 21 15 20 17 22 0.93
Unemployed 22 14 10 13 12 15
Retired/Home 18 12 9 12 9 11
Disability 66 42 32 42 34 43
Other 17 11 10 13 7 9
Education Level N % N % N %
< High school/some 27 18 15 20 12 15 0.33
High school degree 53 34 22 29 31 39
Some college/AA degree 53 34 30 39 23 29
College degree or > 22 14 9 12 13 17
�Four withdrew consent to use their data after randomization
https://doi.org/10.1371/journal.pone.0225540.t001
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friends, work conflict, lack of child-care, weather, and doctor’s appointments. The most com-
mon reason participants missed a session was that they were “too sick or in “too much pain to
come”. Participants in the intervention group who attended few (4 or less) sessions differed
from those who had high attendance (Tables A and B in S1 Appendix). They were younger
Table 2. Baseline outcomes for all participants by intervention and control group.
Variable (range) ^ Intervention Baseline
(N = 76)
Control Baseline
(N = 79)
Mean (SD) Mean (SD) P-value
Average pain (0–10) 7 (1.9) 7 (1.9) 0.97
BPI Interference (0–10) 7 (2.2) 6 (2.3) 0.47
BPI Severity (0–10) 7 (1.9) 7 (1.8) 0.95
PHQ (0–27) 13 (5.6) 11 (5.3) 0.11
Pain Self-Efficacy (0–60) 30 (15.4) 32 (13.5) 0.47
Patient Activation Measure (0–100) 60 (15.6) 56 (11.8) 0.05�
SF-12 Physical Composite Score (0–100) 33 (10.3) 35 (10.6) 0.12
SF-12 Mental Composite Score (0–100) 35 (9.5) 36 (10.3) 0.62
Current Opioid Misuse Measure (0–64) 11 (5.9) 9 (5.8) 0.05�
N % N % P-value
Pain medication past 7 days 67 88 65 82 0.30
Emergency Department Use 15 21 11 14 0.28
�Significant differences between the intervention and control group for PAM (p = 0.0513), COMM (p = 0.0495) at a
significant level of 0.1, so they were adjusted for in all subsequent models.
^Continuous variables are summarized with mean (standard deviation)
https://doi.org/10.1371/journal.pone.0225540.t002
Table 3. Outcomes for 9 weeks for all participants by intervention and control group.
Outcomes for Specific Aim 1 (Reduction of Pain)
Variable (range) Intervention Baseline
(N = 69)
Control Baseline
(N = 69)
Total
(N = 138)
Mean (SD) Mean (SD) P-value Mean (SD)
Average pain (0–10) 6 (2.3) 6 (2.0) 0.61 6 (2.1)
BPI Interference (0–10) 6 (2.8) 5 (2.5) 0.64 6 (2.7)
BPI Severity (0–10) 6 (2.2) 6 (2.2) 0.94 6 (2.2)
Outcome for Specific Aim 2 (Reduction of Depression)
PHQ (0–27) 11 (5.5) 10 (5.7) 0.15 10 (5.6)
Outcomes for Specific Aim 3 (Increase of Pain Self-Efficacy and Reduced Use of Pain Medication)
Pain Self-Efficacy (0–60) 36 (15.7) 34.8 (14.1) 0.68 35 (14.8)
n % n % P-value n %
Pain medication past 7 days 53 77 54 78 0.84 107 78
Secondary Self Report Outcomes
Mean (SD) Mean (SD) P-value Mean (SD)
Perceived Stress Scale (0–16) 7 (3.3) 7 (3.7) 0.85 7 (3.5)
Patient Activation Measure (0–100) 61 (13.6) 62 (16.4) 0.58 62 (15.0)
SF-12 Physical Composite Score (0–100) 36 (10.1) 37 (10.4) 0.68 36 (10.2)
SF-12 Mental Composite Score (0–100) 36 (9.9) 39 (11.4) 0.22 37 (10.7)
Current Opioid Misuse Measure (0–64) 9 (6.4) 8 (6.0) 0.22 9 (6.2)
n % n % P-value n %
Emergency Department Use 6 8 13 16 0.13 19 13
https://doi.org/10.1371/journal.pone.0225540.t003
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Table 4. Outcomes for 21 weeks for all participants by intervention and control group.
Outcomes for Specific Aim 1 (Reduction of Pain)
Variable (range) Intervention Baseline
(N = 68)
Control Baseline
(N = 72)
Total
(N = 140)
Mean (SD) Mean (SD) P-value Mean (SD)
Average pain (0–10) 6 (2.0) 6 (2.0) 0.64 6 (2.0)
BPI Interference (0–10) 6 (2.7) 5 (2.7) 0.046� 5 (2.7)
BPI Severity (0–10) 6 (2.3) 6 (2.0) 0.96 6 (2.1)
Outcome for Specific Aim 2 (Reduction of Depression)
PHQ (0–27) 9 (5.4) 10 (5.9) 0.39 10 (5.7)
Outcomes for Specific Aim 3 (Increase of Pain Self-Efficacy and Reduced Use of Pain Medication)
Pain Self-Efficacy (0–60) 34 (14.7) 38 (13.5) 0.10 36 (14.2)
n % n % P-value n %
Pain medication past 7 days 49 72 60 83 0.11 109 78
Secondary Self Report Outcomes
Mean (SD) Mean (SD) P-value Mean (SD)
Perceived Stress Scale (0–16) 7 (3.3) 7 (3.4) 0.83 7 (3.3)
Patient Activation Measure (0–100) 62 (13.5) 63 (16.2) 0.69 62 (14.9)
SF-12 Physical Composite Score (0–100) 33 (11.0) 38 (9.7) 0.006� 36 (10.6)
SF-12 Mental Composite Score (0–100) 41 (11.6) 38 (11.3) 0.19 40 (11.5)
Current Opioid Misuse Measure (0–64) 9 (6.1) 8 (5.2) 0.28 8 (5.6)
n % n % P-value n %
Emergency Department Use 9 12 9 11 0.86 18 12
�indicates that the results are statistically significant
https://doi.org/10.1371/journal.pone.0225540.t004
Table 5. Intention to treat results for outcome data.
Week 9
Relative Risk (CI)
Week 21
Relative Risk (CI)
RR without time interaction term of 9 week and 21 weeks, if it is not significant
Average painp 1.03 (0.92, 1.15) 0.98 (0.88, 1.08) 1.00 (0.92, 1.08)
BPI Interferencep 1.00 (0.86, 1.16) 1.17 (0.99,1.37) 1.06 (0.96, 1.18)
BPI Severityp 1.00 (0.89, 1.13) 1.01 (0.90, 1.14) 1.01 (0.92, 1.10)
PHQ-9† 1.09 (0.92, 1.28) 0.89 (0.75, 1.06) Interaction is significant
Pain Self Efficacy† 1.09 (0.96, 1.25) 0.93 (0.83, 1.05) Interaction is significant
Patient Activation Measurep 0.99 (0.92, 1.07) 1.00 (0.93, 1.08) Interaction is significant
SF-12 Physical Composite ScoreL 1.01 (0.92, 1.12) 0.86 (0.77, 0.97)� Interaction is significant
SF-12 Mental Composite ScoreL 1.01 (0.95, 1.07) 1.07 (1.01, 1.12)� 1.02 (0.96, 1.08)
Current Opioid Misuse Measurep 1.14 (0.92, 1.42) 1.13 (0.91, 1.40) 1.20 (1.10, 1.42)
Pain medication in the last 7 days
(Odds Ratio)
0.75 (0.33, 1.68) 0.42 (0.18, 0.98)� Interaction is significant
ED usep 0.31 (0.10, 0.89)� 0.85 (0.32, 2.22) 0.72 (0.41,1.26)
p Poisson Model was used for this outcome variable.
† Negative Binomial Model was used for this outcome variable.
L Log Normal Model was used for this outcome variable.
OR Logistic regression model was use for this outcome variable. The results are OR (95%CI).
� Results are statistically significant and 95% Confidence Intervals (CI) does not include the number 1. All models were adjusted for COMM, PAM and this table shows
the “9 week” and “21 week” results. The control group as well as the baseline outcomes were set as reference groups.
https://doi.org/10.1371/journal.pone.0225540.t005
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(mean 41 years old), more likely to be female (92%), and reported higher pain, pain severity,
and depressive symptoms (PHQ-9 mean = 14.23) than those attending 5 or more groups. Par-
ticipants in the control group who did not attend a primary care provider appointment during
the study (n = 17) were different from the controls who did (n = 62). They were younger (42
years old compared with 54 years old) and used less pain medication than those who did see
their PCP.
In the exploratory attendance multivariable regression analysis, we compared intervention
participants with different attendance to the control participants who did not visit PCP.
Among those who attended 5–6 sessions [RR: 0.80, 95%CI: 0.67, 0.97] or 7–10 sessions [RR:
0.87, 95%CI: 0.76, 1.00, p = 0.05] there was a reduction in average pain. Among participants
who attended 5–6 sessions, there was a 28% reduction in PHQ-9 scores at 9 weeks [RR: 0.72,
95% CI: 0.54, 0.97] and a 33% reduction of PHQ-9 scores at 21 weeks [RR: 0.67, 95% CI: 0.47,
0.95] compared to control, which translated into a clinically meaningful result of 4.8 points dif-
ference. Participants who attended 7–10 sessions had a 30% reduction in PHQ-9 scores and
reduced their opioid use from 42% to 28%.
Adverse events
Forty-one adverse events occurred in 13 participants in the control group and 19 participants
in the intervention group. The most common adverse events were ED visits (11 in the inter-
vention and 17 in the control group). There were two hospital admissions from both the inter-
vention and the control group. Among the 41 adverse events, 40 were determined to be
unrelated to the intervention. The one event determined to be due to the intervention was
when a participant fell off a swivel chair during a group visit. This participant was not harmed.
Fidelity and evaluation data
Each group was scored with a monitoring and evaluation checklist by a research assistant for
fidelity. The checklist monitored adherence to vitals, centering meditation, delivery of health
topic, mind-body activity, and the review of home practice. The maximum possible fidelity
score per group is 80. Across the seven cohorts the average fidelity score was 77.3.
Discussion
This RCT tested the effectiveness of a 21-week mind body self-management medical group
visit in a socioeconomic diverse patient population with chronic pain and depressive symp-
toms and found no different in pain and depressive symptoms compared to primary care vis-
its, with both groups experiencing improvement in symptoms. There was a significant
reduction in pain medication use and increase in mental quality of life attributable to the inter-
vention as well as a reduction in total ED visits, reproducing our previous findings of
decreased ED utilization [69]. Although the primary outcome of pain and depressive symp-
toms were not different from a primary care visit, decreased ED use and pain medication use
suggest IMGV may be helpful in patients with chronic pain and depression. The study further
demonstrates that IMGVs are viable in urban outpatient clinics and CHCs (94% attended at
least one IMGV, 72% attended half or more sessions.
Chronic pain places a burden on patients’ lives with many patients also suffering from
depression [70]. Clinical studies have shown a reduction in depressive symptoms as a second-
ary outcome [71–74]. In clinical trials on chronic pain and MGVs in low-income patients, our
lack of significant reduction in pain is inconsistent with prior studies. For example, Geller
et al. conducted a prospective cohort study of MGVs for 42 women in a low-income patient
population and showed changes in bodily pain and mental health. [75,76]. Chao et al.,
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conducted a prospective RCT of the effectiveness of a 7-week MGV or an educational booklet
control condition in 45 older women with nonspecific chronic pelvic pain [77] and found a
reduction in pain intensity immediately following the group sessions [78]. Our study incorpo-
rated participants with depressive symptoms and chronic pain, which increases comorbidity;
therefore, this was a more difficult population to treat then in previous published studies above.
In the U.S., current treatment options for chronic pain are largely medication-based (opi-
oids) despite mixed evidence of efficacy and increased risk of potentially dangerous side
effects, including addiction and death [24,25, 79–83]. In this study, a statistically significant
reduction in pain medication use occurred in the intervention compared with the control
group. Other MGVS studies have found showed a reduction in pain medication use [71,84].
Chronic pain often leads to poor quality of life and frequent health care utilization [26].
The IMGV showed a significant reduction in ED visits between intervention and control
groups at 9 weeks and a non-significant reduction at 21 weeks, suggesting that the active inter-
action with the clinician at the IMGV may offer opportunities to intervene on subacute issues
prior to requiring an ED visit [69]. MGVs have consistently showed a reduction in ED visits,
and suggest that the MGVs have the potential to reduce health care costs [85–90]. Literature
also supports that pain education, present in this intervention, can contribute to lower health-
care utilization and may provide additional explanation for the reduction in ED visits [91].
The IMGV was helpful to patient’s mental quality of life at 21 weeks, which may be attributable
to a reduction in isolation and increase in emotional support [76, 90, 92–93]. The IMGV was
protective during the group visit because the participants had access to a clinician and social
support.
Based on our previous attendance to clinical group visits, we did not anticipate the variety
of different levels of attendance to the IMGV or to the PCP (control). Although asked to visit
their PCP clinician, 17 control participants did not attend any PCP visits during the course of
the study. Those in the control group who did not visit their PCP during the study were youn-
ger and more depressed with higher pain scores, consistent with trends seen elsewhere [94].
Participants who attended few MGVs were clinically different from those who had high atten-
dance. Since low attendance participants had the highest average pain at baseline—this may
have been a factor affecting their mobility and ability to attend a minimum number of groups.
Not all patients are the right candidates for medical group visits, and it is important to deter-
mine who will come to a MGV and who will not [95]. To design the appropriate group inter-
vention, it is important to recognize participants with low attendance and the factors that
differentiate them from other participants in the study [96–98].
Limitations of the study
There are several limitations in this RCT that may have affected the outcomes of the study. For
example, it is possible that 9 weeks of active in-person group visits was not long enough to see
a significant change when comparing a routine primary care to medical group visit. In addi-
tion, at enrollment, some patients may have heightened pain and depressive symptoms, and as
time went on, their scores may have regressed to the mean. We also used self-reported mea-
surements for pain and depression, and these can change day-to-day. Another limitation is
that we did not have the statistical power to conduct a multi-variable regression for reduction
in opioids and NSAIDS because of our small sample size. We performed many analyses and it
is possible that the results could appear significant by chance alone. We suggest that these
results be taken as suggestive and hypothesis generating for future studies.
In conclusion, MGVs are one way to incorporate patient self-management, non-pharmaco-
logical techniques, pain education, and increase social connections into the health care system
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[99–101]. When comparing groups that attended MGVs or had a PCP visit, both showed a
similar reduction in self-reported pain and depressive symptoms. However, our results suggest
that IMGV is a feasible adjunct model of care for low-income diverse patients and is more
effective than a PCP visit at reducing ED visits and pain medications.
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